FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	

hours per response:

0.5

3 ,	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
	Estimated average burd	en		

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GARCEAU ROGER					2. Issuer Name and Ticker or Trading Symbol Protara Therapeutics, Inc. [TARA]										tionship of all applications	able)	g Pers	son(s) to Iss		
(Last) (First) (Middle) C/O PROTARA THERAPEUTICS, INC. 1 LITTLE WEST 12TH STREET					3. Date of Earliest Transaction (Month/Day/Year) 06/09/2020										Officer (give title below)		Other (s _l below)		pecify	
(Street) NEW YORK NY 10014 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date				2. Transac	Execution Date,			3. Transac Code (Ir 8)	tion	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		ed (A) or str. 3, 4 ar) or 4 and Securiti Benefic Owned Reporte		es (D) (Forrially (D) (Following distribution(s)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Yo	Date, Transa Code					6. Date Exe Expiration I (Month/Day	Date		e and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Pric Deriva Securi (Instr.		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares	r						
Stock Option (Right to Buy)	\$35	06/09/2020			A		9,000		(1)	06	6/08/2030	Common Stock	9,000		\$0.00	9,000		D		

Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

/s/ Jesse Shefferman, Attorney-06/10/2020 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.